Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 556

1.

Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.

Pisanu A, Lecca D, Mulas G, Wardas J, Simbula G, Spiga S, Carta AR.

Neurobiol Dis. 2014 Nov;71:280-91. doi: 10.1016/j.nbd.2014.08.011. Epub 2014 Aug 15.

PMID:
25134730
2.

Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.

Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E.

Neuroscience. 2011 Oct 27;194:250-61. doi: 10.1016/j.neuroscience.2011.07.046. Epub 2011 Jul 27.

PMID:
21839812
3.

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR.

Eur J Neurosci. 2009 Mar;29(5):954-63. doi: 10.1111/j.1460-9568.2009.06657.x. Epub 2009 Feb 24.

PMID:
19245367
4.

Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR.

Neurotox Res. 2009 Aug;16(2):127-39. doi: 10.1007/s12640-009-9061-x. Epub 2009 May 27.

PMID:
19526289
5.

Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.

Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S.

Neurotox Res. 2009 May;15(4):332-47. doi: 10.1007/s12640-009-9037-x. Epub 2009 Mar 17.

PMID:
19384567
6.

Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

Wang S, Jing H, Yang H, Liu Z, Guo H, Chai L, Hu L.

J Ethnopharmacol. 2015 Apr 22;164:247-55. doi: 10.1016/j.jep.2015.01.042. Epub 2015 Feb 7.

PMID:
25666429
7.

Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.

Lee EY, Lee JE, Park JH, Shin IC, Koh HC.

Toxicol Lett. 2012 Sep 18;213(3):332-44. doi: 10.1016/j.toxlet.2012.07.016. Epub 2012 Jul 27.

PMID:
22842585
8.

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J.

J Neurochem. 2006 Apr;97(2):435-48. Epub 2006 Mar 15.

9.

Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease.

Zhao YF, Zhang Q, Xi JY, Li YH, Ma CG, Xiao BG.

J Neurol Sci. 2015;353(1-2):28-37. doi: 10.1016/j.jns.2015.03.022. Epub 2015 Mar 20.

PMID:
25908255
10.
11.

Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.

Lecca D, Nevin DK, Mulas G, Casu MA, Diana A, Rossi D, Sacchetti G, Carta AR.

Neuroscience. 2015 Aug 27;302:23-35. doi: 10.1016/j.neuroscience.2015.04.026. Epub 2015 Apr 20.

PMID:
25907448
12.
13.

α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease.

Kim BW, Koppula S, Kumar H, Park JY, Kim IW, More SV, Kim IS, Han SD, Kim SK, Yoon SH, Choi DK.

Neuropharmacology. 2015 Oct;97:46-57. doi: 10.1016/j.neuropharm.2015.04.037. Epub 2015 May 15.

PMID:
25983275
14.

Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.

Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG.

J Neuroinflammation. 2012 Oct 23;9:241. doi: 10.1186/1742-2094-9-241.

15.

Immunomodulatory and neuroprotective effects of ginsenoside Rg1 in the MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) -induced mouse model of Parkinson's disease.

Zhou TT, Zu G, Wang X, Zhang XG, Li S, Liang ZH, Zhao J.

Int Immunopharmacol. 2015 Dec;29(2):334-43. doi: 10.1016/j.intimp.2015.10.032. Epub 2015 Nov 6.

PMID:
26548343
16.

Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Olson KE, Kosloski-Bilek LM, Anderson KM, Diggs BJ, Clark BE, Gledhill JM Jr, Shandler SJ, Mosley RL, Gendelman HE.

J Neurosci. 2015 Dec 16;35(50):16463-78. doi: 10.1523/JNEUROSCI.2131-15.2015.

17.

Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.

Barbiero JK, Santiago RM, Persike DS, da Silva Fernandes MJ, Tonin FS, da Cunha C, Lucio Boschen S, Lima MM, Vital MA.

Behav Brain Res. 2014 Nov 1;274:390-9. doi: 10.1016/j.bbr.2014.08.014. Epub 2014 Aug 13.

PMID:
25127682
18.

Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.

Laloux C, Petrault M, Lecointe C, Devos D, Bordet R.

Pharmacol Res. 2012 May;65(5):514-22. doi: 10.1016/j.phrs.2012.02.008. Epub 2012 Mar 3.

PMID:
22391246
19.

Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses.

Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V, Dragone T, Calvello R, Panaro MA.

Innate Immun. 2014 Apr;20(3):249-60. doi: 10.1177/1753425913488429. Epub 2013 Jun 13.

PMID:
23764428
20.

Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson's disease.

Galuppo M, Iori R, De Nicola GR, Bramanti P, Mazzon E.

Bioorg Med Chem. 2013 Sep 1;21(17):5532-47. doi: 10.1016/j.bmc.2013.05.065. Epub 2013 Jun 11.

PMID:
23810671

Supplemental Content

Support Center